US2017360798A1PendingUtilityA1

Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection

58
Assignee: ANAVEX LIFE SCIENCES CORPPriority: Mar 28, 2013Filed: Sep 5, 2017Published: Dec 21, 2017
Est. expiryMar 28, 2033(~6.7 yrs left)· nominal 20-yr term from priority
Inventors:Alexandre VamvakidesTangui Maurice
A61K 31/27A61K 31/341A61K 31/495A61K 31/34A61K 45/06C07D 307/14A61K 31/445A61K 31/55A61K 31/13A61K 31/44A61K 31/435
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.

Claims

exact text as granted — not AI-modified
1 . A dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine. 
     
     
         2 . The dosage form of  claim 1  wherein said neuroprotective amount of A2-72 is from about 0.5 to about 20 mg. 
     
     
         3 . The dosage form of  claim 1  wherein said at least one cooperating acetylcholinesterase inhibitor is donepezil. 
     
     
         4 . The dosage form of  claim 3  wherein the neuroprotective amount of donepezil is from about 0.5 mg to about 23 mg. 
     
     
         5 . The dosage form of  claim 4  wherein the neuroprotective amount of donepezil is from about 0.5 mg to less than about 5 mg. 
     
     
         6 . The dosage form of  claim 5  wherein the neuroprotective amount of donepezil is from about 1 to about 3.5 mg. 
     
     
         7 . The dosage form of  claim 1  wherein said at least one cooperating acetylcholinesterase inhibitor is galantamine. 
     
     
         8 . The dosage form of  claim 7  wherein the neuroprotective amount of galantamine is from about 0.5 mg to about 20 mg. 
     
     
         9 . The dosage form of  claim 1  wherein said at least one cooperating acetylcholinesterase inhibitor is galantamine. 
     
     
         10 . The dosage form of  claim 9  wherein the neuroprotective amount of galantamine is from about 0.5 mg to about 20 mg. 
     
     
         11 . The dosage form of  claim 1  wherein said at least one cooperating acetylcholinesterase inhibitor is rivastagmine. 
     
     
         12 . The dosage form of  claim 11  wherein the neuroprotective amount of rivastagmine is from about 0.5 mg to about 20 mg. 
     
     
         13 . The dosage form of  claim 1  wherein said at least one cooperating acetylcholinesterase inhibitor is memantine. 
     
     
         14 . The dosage form of  claim 13  wherein the neuroprotective amount of memantine is from about 0.5 mg to about 30 mg. 
     
     
         15 . A therapeutic method of neuroprotection in a subject with actual or anticipated neuronal injury comprising administering a neuroprotective dose of A2-73 in conjunction with at least one neuroprotective dose selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine. 
     
     
         16 . The method of  claim 15  wherein said neuroprotective amount of A2-72 is from about 0.5 to about 20 mg. 
     
     
         17 . The method of  claim 15  wherein said at least one cooperating acetylcholinesterase inhibitor is donepezil. 
     
     
         18 . The method of  claim 17  wherein the neuroprotective amount of donepezil is from about 0.5 mg to about 23 mg. 
     
     
         19 . The method of  claim 18  wherein the neuroprotective amount of donepezil is from about 0.5 mg to less than about 5 mg. 
     
     
         20 . The method of  claim 19  wherein the neuroprotective amount of donepezil is from about 1 to about 3.5 mg. 
     
     
         21 . The method of  claim 15  wherein said at least one cooperating acetylcholinesterase inhibitor is galantamine. 
     
     
         22 . The method of  claim 21  wherein the neuroprotective amount of galantamine is from about 0.5 mg to about 20 mg. 
     
     
         23 . The method of  claim 15  wherein said at least one cooperating acetylcholinesterase inhibitor is rivastagmine. 
     
     
         24 . The method of  claim 23  wherein the neuroprotective amount of rivastagmine is from about 0.5 mg to about 20 mg. 
     
     
         25 . The method of  claim 15  wherein said at least one cooperating acetylcholinesterase inhibitor is metamine.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.